Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Preventing venous thromboembolism].

A Encke1, S Haas

  • 1Chirurgische Universitätsklinik Frankfurt/Main, Theodor Stern Kai 7, 60590 Frankfurt/Main. A.Encke@em.uni-frankfurt.de

Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen
|February 1, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Not Available].

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·2014
Same author

Measurement of the azimuthal angle dependence of inclusive jet yields in Pb+Pb collisions at √(sNN)=2.76 TeV with the ATLAS detector.

Physical review letters·2013
Same author

Observation of associated near-side and away-side long-range correlations in sqrt[s(NN)]=5.02 TeV proton-lead collisions with the ATLAS detector.

Physical review letters·2013
Same author

Venous thromboembolism: prophylactic and therapeutic practice guideline.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2013
Same author

Search for dark matter candidates and large extra dimensions in events with a photon and missing transverse momentum in pp collision data at sqrt[s]=7 TeV with the ATLAS detector.

Physical review letters·2013
Same author

Measurement of Z boson production in Pb-Pb collisions at sqrt[s(NN)]=2.76  TeV with the ATLAS detector.

Physical review letters·2013
Same journal

[S3 Guideline "Adult soft tissue sarcomas"].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2022
Same journal

[Synopsis-S3 guidelines pancreatic cancer].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2022
Same journal

[Laparoscopic sentinel node navigation surgery in gastric cancer to reduce surgical radicality].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2022
Same journal

[Future concepts for neoadjuvant and adjuvant treatment of (resectable) pancreatic cancer].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2022
Same journal

[ASCO guidelines for the treatment of stage III NSCLC part 4: indications for adjuvant therapy].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2022
Same journal

[Surgical treatment of pancreatic cancer-What is new?]

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2022
See all related articles

Antithrombotic prophylaxis is crucial in surgery, tailored to patient risk factors. New anticoagulants may offer improved safety and efficacy over current heparin-based treatments.

Area of Science:

  • Medical science
  • Pharmacology
  • Surgical care

Background:

  • Antithrombotic prophylaxis is standard in surgical treatment.
  • Prophylaxis selection is based on individual thromboembolic risk.
  • Risk is determined by patient-specific factors and procedure-related elements.

Purpose of the Study:

  • To review the current landscape of antithrombotic prophylaxis in surgery.
  • To discuss the risk stratification for thromboembolic events.
  • To highlight the limitations of existing treatments and the potential of new agents.

Main Methods:

  • Review of current clinical practices in antithrombotic prophylaxis.
  • Analysis of risk factors influencing thromboembolic events.
  • Evaluation of established prophylactic agents (heparins) and emerging anticoagulants.

Related Experiment Videos

Main Results:

  • Thromboembolic risk is categorized into low, moderate, and high, guiding prophylaxis.
  • Unfractionated heparin and low molecular weight heparins are effective but have side effects.
  • New anticoagulant agents show promise for improved prophylaxis.

Conclusions:

  • Risk-adapted antithrombotic prophylaxis is essential in surgical patients.
  • Current heparin-based prophylaxis has limitations.
  • Novel anticoagulants may offer enhanced antithrombotic strategies with fewer adverse effects.